

HYBRIGENICS

Press release

Hybrigenics receives green light for its European patent on high therapeutic doses of inecalcitol

Paris, January 24, 2011 – Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments, today announces it has received from the European Patent Office the official notification of its intent to grant Hybrigenics' patent on therapeutic uses of high doses of inecalcitol, under an accelerated procedure.

Originally filed in 2009, this patent will cover inecalcitol doses higher than one milligram (mg) per day until 2029. Currently-marketed vitamin D analogues for their usual indications such as rickets, osteoporosis or chronic kidney disease do not exceed 10 microgram (μg) per day, *i.e.* 100 times lower doses. The maximal tolerated dose of inecalcitol has been established at 4 mg per day in hormone-refractory prostate cancer patients. The ability to treat patients with a vitamin D analogue in the milligram dose range is totally new. This makes inecalcitol uniquely suited to reach efficacious levels without side effects in new challenging indications such as cancer or psoriasis by oral administration.

The same patent application is still under examination by the United States Patent and Trademark Office and by the World Intellectual Property Organization under the Patent Cooperation Treaty (PCT) procedure, to get full worldwide protection. *"This patent stems from proprietary findings generated by Hybrigenics and will be further strengthening the existing intellectual property position of inecalcitol for 20 years,"* said Rémi Delansorne, Hybrigenics' CEO.

About Hybrigenics (ISIN: FR0004153930, Ticker: ALHYG)

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics is also the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS

Press release

**HYBRIGENICS IS LISTED ON THE ALTERNEXT BY NYSE
EURONEXT Paris**

ISIN : FR0004153930

Mnémo : ALHYG



Hybrigenics
Rémi Delansorne
Directeur Général
Tél. : +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.
Communication financière
Axelle Vuillermet / Pierre Laurent
Tél. : +33 (0)1 44 71 94 94
hybrigenics@newcap.fr